PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
2.78M / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.68%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-69.03%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
91.08%
OCF/share CAGR of 91.08% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-120.06%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-128.37%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
98.98%
10Y net income/share CAGR of 98.98% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
76.84%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
77.05%
Positive short-term CAGR while CRN.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
-68.22%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
48.56%
Positive 5Y equity/share CAGR while CRN.AX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
297.14%
Positive short-term equity growth while CRN.AX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.